Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cancer Therapy

The seed extension financing was led by Three Rivers Capital, who joins existing private Chinese investors.